Brief reportA low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes
Introduction
Dipeptidyl peptidase-4 inhibitors (DPP-4i) are a new class of therapeutic agent for the treatment of type 2 diabetes (T2DM). DPP-4i exert their action through potentiation of activity of incretin hormones such as glucagon-like peptide-1 (GLP-1) [1], [2]. However some adverse effects of DPP-4i have been reported and there has been concern about increased risk of pancreatitis and pancreatic cancer [3], [4], [5]. Although studies in a rat model of T2DM showed an adverse effect of DPP-4i on the exocrine pancreas such as ductal metaplasia and pancreatitis [6], more information is needed in humans. The purpose of this study was to determine possible adverse effects of DPP-4i on the exocrine pancreas in patients with T2DM.
Section snippets
Subjects
Twenty four Japanese patients (14 male and 10 female, mean age 61.9 years) with T2DM taking DPP-4i as a first or additional drug were enrolled to the study. HbA1c ranged from 7.0% (53 mmol/mol) – 9.0% (75 mmol/mol) and they had not start taking any new drugs or changed medication within the previous 2 months.
Twelve matched patients (6 male and 6 female, mean age 60.1 years) taking metformin were selected retrospectively as a historical control group. None had severe cardiac, renal, or hepatic
Results
DPP-4i treatment significantly decreased HbA1c from 7.5 ± 0.2% (59 ± 2 mmol/mol) at 0 week to 7.0 ± 0.2% (53 ± 2 mmol/mol) at 8 weeks (p < 0.01). HbA1c lowering was not significantly different between sitagliptin and alogliptin treated subjects (0.6 ± 0.1 and 0.6 ± 0.1%, p = 0.86 at 8 weeks; 0.5 ± 0.2 and 0.7 ± 0.2%, p = 0.50 at 24 weeks). In the metformin group HbA1c improved significantly and similar to the DPP-4i group (from 7.6 ± 0.1%, 60 ± 1 mmol/mol at 0 week to 7.1 ± 0.2%, 54 ± 2 mmol/mol at 8 weeks; p < 0.01). None of the
Discussion
In this study serum pancreatic exocrine enzyme activity increased slightly but significantly during treatment with DPP-4i. Furthermore the change of P-amylase activity related positively with leukocyte number and neutrophil number/percentage and negatively with lymphocyte percentage. These results suggest that DPP-4i potentially cause a low-grade subclinical asymptomatic inflammatory change with the pancreas.
Acute pancreatitis has been raised as a possible adverse effect of DPP-4i but there is
Conflict of interest
The authors declare that they have no conflict of interest.
Acknowledgments
We thank SRL Corporation (Tokyo, Japan) and Mr. Yuuta Eiraku for their support of sample analysis, Dr. Koutaro Yokote, Tatsuhiko Tokuyama, Toshitake Tokuyama, Takahiko Tokuyama and all member of B4 Laboratory for useful discussion, and Clinical Research Coordinators of Chiba Medical Center for management of the clinical study.
References (10)
- et al.
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Gastroenterology
(2011) - et al.
Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?
Diabetes Res Clin Pract
(2010) - et al.
Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting
Endocr Pract
(2012) - et al.
Incretin-based therapies: viewpoints on the way to consensus
Diabetes Care
(2009) - et al.
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits
Diabetes Care
(2010)
Cited by (16)
Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus
2017, Diabetes Research and Clinical PracticeCitation Excerpt :Therefore, the anti-inflammatory effects of DPP-4i might be partially dependent on the stabilized GLP-1 molecule. Although our study indicated that DPP4i seemed to possess anti-inflammatory properties, a recent study reported that DPP4i might increase in patients who have suffered heart failure [29], affects pancreatic exocrine function [30], and is reportedly associated with the development of Bullous pemphigoid [31]. It has been reported that treatment with sitagliptin for 12 weeks decreased the number of Th17 and Treg cells among Japanese patients with diabetes [32].
Overview of Inpatient Management of Hypertriglyceridemia Associated Acute Pancreatitis in Patients with Diabetes Mellitus
2023, Contemporary EndocrinologyComparison of amylase and lipase levels of patients with Type 2 diabetes under different treatment modalities
2022, Biomarkers in MedicineSafety of Semaglutide
2021, Frontiers in EndocrinologyThe relationship between dipeptidyl peptidase-4 inhibitor usage and asymptomatic amylase lipase increment in type 2 diabetes mellitus patients
2020, Turkish Journal of Pharmaceutical Sciences